Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance

Ajumeera, Rajanna; Ajmeera, Divya

doi:10.1016/j.gendis.2022.12.013

Cited by 22 publications

(7 citation statements)

References 247 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While targeted therapies aim to selectively inhibit specific molecular pathways involved in cancer progression, achieving sufficient specificity presents a significant challenge. Off-target effects and unintended interactions with normal tissues can lead to adverse side effects and compromise the therapeutic window of precision medicine drugs. , Striking the right balance between targeting cancer-specific pathways and minimizing the impact on healthy tissues is crucial for the safety and success of precision medicine interventions. The molecular heterogeneity of colorectal cancer further complicates the landscape of drug specificity.…”

Section: Challenges and Considerations In Precision Medicine Implemen...mentioning

confidence: 99%

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Kiran,

Yashaswini,

Maheshwari

et al. 2024

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Precision medicine is transforming colorectal cancer treatment through the integration of advanced technologies and biomarkers, enhancing personalized and effective disease management. Identification of key driver mutations and molecular profiling have deepened our comprehension of the genetic alterations in colorectal cancer, facilitating targeted therapy and immunotherapy selection. Biomarkers such as microsatellite instability (MSI) and DNA mismatch repair deficiency (dMMR) guide treatment decisions, opening avenues for immunotherapy. Emerging technologies such as liquid biopsies, artificial intelligence, and machine learning promise to revolutionize early detection, monitoring, and treatment selection in precision medicine. Despite these advancements, ethical and regulatory challenges, including equitable access and data privacy, emphasize the importance of responsible implementation. The dynamic nature of colorectal cancer, with its tumor heterogeneity and clonal evolution, underscores the necessity for adaptive and personalized treatment strategies. The future of precision medicine in colorectal cancer lies in its potential to enhance patient care, clinical outcomes, and our understanding of this intricate disease, marked by ongoing evolution in the field. The current reviews focus on providing in-depth knowledge on the various and diverse approaches utilized for precision medicine against colorectal cancer, at both molecular and biochemical levels.

show abstract

Section: Challenges and Considerations In Precision Medicine Implemen...mentioning

confidence: 99%

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Kiran,

Yashaswini,

Maheshwari

et al. 2024

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

show abstract

“…ABC transporters are present in normal cells, but their overexpression in cancer cells increases the chemo/radioresistance of tumors [ 104 ]. CSCs efficiently express ABC transporter proteins, such as MDR1/ABCB1, MRP1/ABCC1, and ABCG2, that belong to multidrug resistance proteins and ensure cancer cells’ resistance to anticancer therapy [ 73 , 105 ]. Moreover, it was reported that CSC populations have efflux ability due to the high activity of ABC transporters and ALDH, which decreases oxidative stress and increases resistance to cytotoxic agents [ 6 , 24 ].…”

Section: Cscs In Head and Neck Cancermentioning

confidence: 99%

The Role of Hedgehog Signaling Pathway in Head and Neck Squamous Cell Carcinoma

Cierpikowski,

Leszczyszyn,

Bar

2023

Cells

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is the sixth leading malignancy worldwide, with a poor prognosis and limited treatment options. Molecularly targeted therapies for HNSCC are still lacking. However, recent reports provide novel insights about many molecular alterations in HNSCC that may be useful in future therapies. Therefore, it is necessary to identify new biomarkers that may provide a better prediction of the disease and promising targets for personalized therapy. The poor response of HNSCC to therapy is attributed to a small population of tumor cells called cancer stem cells (CSCs). Growing evidence indicates that the Hedgehog (HH) signaling pathway plays a crucial role in the development and maintenance of head and neck tissues. The HH pathway is normally involved in embryogenesis, stem cell renewal, and tissue regeneration. However, abnormal activation of the HH pathway is also associated with carcinogenesis and CSC regulation. Overactivation of the HH pathway was observed in several tumors, including basal cell carcinoma, that are successfully treated with HH inhibitors. However, clinical studies about HH pathways in HNSCC are still rare. In this review, we summarize the current knowledge and recent advances regarding the HH pathway in HNSCC and discuss its possible implications for prognosis and future therapy.

show abstract

“…Several methods have been described for selective drug loading and delivery: bacteria, viruses, cells, polymer-based or synthetic lipid carrier systems as well as extracellular vesicles [ 2 ]. Mesenchymal stromal cells (MSC) represent a family of undifferentiated multipotent adult cells presenting wide self-renewal features and the capacity to differentiate into an assortment of mesenchymal lineage cells [ 3 , 4 ]. They show wide-ranging anti-inflammatory and immunomodulatory effects on the immune system and-after transplantation-are able to cross-talk with the local microenvironment, stimulating tissue restoring and regeneration.…”

Section: Introductionmentioning

confidence: 99%

Stem cell technology for antitumor drug loading and delivery in oncology

PETRELLA,

CASSINA,

LIBRETTI

et al. 2024

View full text Add to dashboard Cite

The main aim of antineoplastic treatment is to maximize patient benefit by augmenting the drug accumulation within affected organs and tissues, thus incrementing drug effects and, at the same time, reducing the damage of noninvolved tissues to cytotoxic agents. Mesenchymal stromal cells (MSC) represent a group of undifferentiated multipotent cells presenting wide self-renewal features and the capacity to differentiate into an assortment of mesenchymal family cells. During the last year, they have been proposed as natural carriers for the selective release of antitumor drugs to malignant cells, thus optimizing cytotoxic action on cancer cells, while significantly reducing adverse side effects on healthy cells. MSC chemotherapeutic drug loading and delivery is an encouraging new area of cell therapy for several tumors, especially for those with unsatisfactory prognosis and limited treatment options available. Although some experimental models have been successfully developed, phase I clinical studies are needed to confirm this potential application of cell therapy, in particular in the case of primary and secondary lung cancers.

show abstract

Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance

Cited by 22 publications

References 247 publications

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

The Role of Hedgehog Signaling Pathway in Head and Neck Squamous Cell Carcinoma

Stem cell technology for antitumor drug loading and delivery in oncology

Contact Info

Product

Resources

About